<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00317642</url>
  </required_header>
  <id_info>
    <org_study_id>CLO34100405</org_study_id>
    <secondary_id>2008-001043-19</secondary_id>
    <nct_id>NCT00317642</nct_id>
  </id_info>
  <brief_title>A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)</brief_title>
  <official_title>A Phase III Randomized, Double-blind, Controlled Study Comparing Clofarabine and Cytarabine Versus Cytarabine Alone in Adult Patients 55 Years and Older With Acute Myelogenous Leukemia (AML) Who Have Relapsed or Are Refractory After Receiving up to Two Prior Induction Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the
      treatment of pediatric patients 1 to 21 years old with relapsed acute or refractory
      lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens.

      There is no recommended standard treatment for relapsed or refractory acute myelogenous
      leukemia in older patients. Cytarabine is the most commonly used drug to treat these
      patients. This study will determine if there is benefit by combining clofarabine with
      cytarabine. Patients will be randomized to receive up to 3 cycles of treatment with either
      placebo in combination with cytarabine or clofarabine in combination with cytarabine.
      Randomization was stratified by remission status following the first induction regimen (no
      remission [i.e., CR1 = refractory] or remission &lt;6 months vs CR1 = remission ≥6 months). CR1
      is defined as remission after first pre-study induction regimen. The safety and tolerability
      of clofarabine in combination with cytarabine and cytarabine alone will be monitored
      throughout the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After screening and eligibility assessment, patients were randomized (in a 1:1 ratio) to
      receive either clofarabine or matching placebo, in addition to cytarabine. Randomization was
      stratified by remission status following the first induction regimen (CR1): no remission
      [i.e., CR1 = refractory] or remission &lt;6 months vs remission ≥6 months. During randomization
      by interactive voice response system (IVRS), there were 10 participants misclassified to the
      CR1 &lt;6 months stratum and 12 participants misclassified to CR1 ≥6 months stratum. The error
      did not affect the participants' treatment, only the stratification. Due to the
      misclassification, outcomes that used strata in their analysis were analyzed twice: once with
      the 'randomized stratification' which includes the misclassification and once with the
      'calculated stratification' in which participants appear in the 'correct' strata.

      Two clinical study reports were written for this study.

        1. Clinical study report dated 7 April 2011 includes the entire treatment period of all
           participants plus much of the follow-up. At that time, 33 participants in the
           Clofarabine+cytarabine group and 29 participants in the placebo+cytarabine group were
           still being follow-up post treatment. Results were reported on clinicaltrials.gov in
           August 2011. Outcomes that used strata reported the 'calculated strata' on
           clinicaltrials.gov.

        2. Clinical study report dated 9 July 2012 includes all patient treatment experience plus
           all long-term follow-up (a minimum of 2 years from the end of treatment or until the
           patient died). The study was completed at that time. Outcomes that used strata reported
           the 'randomized strata' on clinicaltrials.gov. AE records on clinicaltrials.gov reflect
           the final database.

      Outcomes that changed between the two clinical study reports due to the additional long-term
      follow-up data are reported twice on clinicaltrials.gov (once from each clinical study
      report) and the appropriate report date is included in the outcome description. Outcomes from
      the 9 July 2012 report represent more complete data.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival - Overall and by Calculated Strata (CSR 7-April-11)</measure>
    <time_frame>Day 1 (randomization) up to approximately 4 years</time_frame>
    <description>Overall survival (OS) for the Full Analysis Set (FAS) and for the 2 calculated strata. OS was defined as the number of months from date of randomization until date of death due to any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival - Overall and by Randomized Strata (CSR 9-July-12)</measure>
    <time_frame>Day 1 (randomization) up to approximately 4 years</time_frame>
    <description>Overall survival (OS) for the Full Analysis Set (FAS) and for the 2 randomized strata. OS was defined as the number of months from date of randomization until date of death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Response Per Independent Response Review Panel (IRRP) Assessment - Overall and by Calculated Strata (CSR 7-April-11)</measure>
    <time_frame>Day 12 up to approximately 6 months</time_frame>
    <description>Percentage of participants whose best response was assessed by the IRRP as complete remission (CR) or complete remission with incomplete peripheral blood count recovery (CRi) using the revised International Working Group for Response Criteria (Cheson 2003).
CR is defined on morphologic criteria at a single response assessment:
a bone marrow aspirate or biopsy of &lt;5% blasts, with evidence of normal hematopoiesis;
absence of Auer rods in the blasts that are present;
absence of extramedullary disease;
absence of a unique phenotype determined at the pretreatment specimen, as assessed by immunophenotyping;
only rare evidence of circulating blasts. If present, evidence of a regenerating bone marrow;
recovery of peripheral counts (platelets ≥100*10^9/L and absolute neutrophil count (ANC) ≥1.0*10^9/L).
CRi met all criteria for CR except for either residual neutropenia (ANC &lt;1.0*10^9/L) or thrombocytopenia (platelet count &lt;100*10^9/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Remission (DOR) Per IRRP Assessment-Overall and by Calculated Strata (CSR 7-April-11)</measure>
    <time_frame>Day 12 to approximately 4 years</time_frame>
    <description>DOR was defined as the time from first CR or CRi to the date of first objective documentation of disease recurrence, initiation of alternative antileukemic therapy [including hematopoietic stem cell transplant] while in remission, or death due to any cause, whichever occurred first.
CR is defined on morphologic criteria at a single response assessment:
a bone marrow aspirate or biopsy of &lt;5% blasts, with evidence of normal hematopoiesis;
absence of Auer rods in the blasts that are present;
absence of extramedullary disease;
absence of a unique phenotype determined at the pretreatment specimen, as assessed by immunophenotyping;
only rare evidence of circulating blasts. If present, evidence of a regenerating bone marrow;
recovery of peripheral counts (platelets ≥100*10^9/L and absolute neutrophil count (ANC) ≥1.0*10^9/L).
CRi met all criteria for CR except for either residual neutropenia (ANC &lt;1.0*10^9/L) or thrombocytopenia (platelet count &lt;100*10^9/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Remission (DOR) Per IRRP Assessment-Overall and by Randomized Strata (CSR 9-July-12)</measure>
    <time_frame>Day 12 to approximately 4 years</time_frame>
    <description>DOR was defined as the time from first CR or CRi to the date of first objective documentation of disease recurrence, initiation of alternative antileukemic therapy [including hematopoietic stem cell transplant] while in remission, or death due to any cause, whichever occurred first.
CR is defined on morphologic criteria at a single response assessment:
a bone marrow aspirate or biopsy of &lt;5% blasts, with evidence of normal hematopoiesis;
absence of Auer rods in the blasts that are present;
absence of extramedullary disease;
absence of a unique phenotype determined at the pretreatment specimen, as assessed by immunophenotyping;
only rare evidence of circulating blasts. If present, evidence of a regenerating bone marrow;
recovery of peripheral counts (platelets ≥100*10^9/L and absolute neutrophil count (ANC) ≥1.0*10^9/L).
CRi met all criteria for CR except for either residual neutropenia (ANC &lt;1.0*10^9/L) or thrombocytopenia (platelet count &lt;100*10^9/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival by IRRP Assessment - Overall and by Calculated Strata (CSR 7-April-11)</measure>
    <time_frame>Day 12 to approximately 4 years</time_frame>
    <description>Disease-free survival was defined as the time from first complete remission (CR) or complete remission with incomplete peripheral blood count recovery (CRi) until the date of first objective documentation of disease recurrence or death due to any cause, whichever occurred first.
See Outcome #3 for definition of CR and CRi.
Disease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival by IRRP Assessment - Overall and by Randomized Strata (CSR 9-July-12)</measure>
    <time_frame>Day 12 to approximately 4 years</time_frame>
    <description>Disease-free survival was defined as the time from first complete remission (CR) or complete remission with incomplete peripheral blood count recovery (CRi) until the date of first objective documentation of disease recurrence or death due to any cause, whichever occurred first.
See Outcome #3 for definition of CR and CRi.
Disease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival by IRRP Assessment - Overall and by Calculated Strata (CSR 7-April-11)</measure>
    <time_frame>Day 1 (randomization) up to approximately 4 years</time_frame>
    <description>Event-free survival (EFS) was defined as the time from randomization to the date of treatment failure, first disease recurrence (for participants who achieved remission), or death due to any cause, whichever occurred first.
Treatment Failure - ≥5% leukemic blasts by bone marrow exam, with no evidence of hematologic response (ie, &lt;30% decrease in % leukemic blasts).
Disease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival by IRRP Assessment - Overall and by Randomized Strata (CSR 9-July-12)</measure>
    <time_frame>Day 1 (randomization) up to approximately 4 years</time_frame>
    <description>Event-free survival (EFS) was defined as the time from randomization to the date of treatment failure, first disease recurrence (for participants who achieved remission), or death due to any cause, whichever occurred first.
Treatment Failure - ≥5% leukemic blasts by bone marrow exam, with no evidence of hematologic response (ie, &lt;30% decrease in % leukemic blasts).
Disease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Four-Month Event-free Survival Per IRRP Assessment - Overall and by Calculated Strata (CSR 7-April-11)</measure>
    <time_frame>Day 1 (randomization) to Day 122</time_frame>
    <description>Four-month event-free survival (EFS) was defined as achieving an EFS of at least 122 days, where EFS is defined as the time from randomization to the date of treatment failure, first disease recurrence (for participants who achieved remission), or death due to any cause, whichever occurred first.
Treatment Failure - ≥5% leukemic blasts by bone marrow exam, with no evidence of hematologic response (ie, &lt;30% decrease in % leukemic blasts).
Disease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Four-Month Event-free Survival Per IRRP Assessment - Overall and by Randomized Strata (CSR 9-July-12)</measure>
    <time_frame>Day 1 (randomization) to Day 122</time_frame>
    <description>Four-month event-free survival (EFS) was defined as achieving an EFS of at least 122 days, where EFS is defined as the time from randomization to the date of treatment failure, first disease recurrence (for participants who achieved remission), or death due to any cause, whichever occurred first.
Treatment Failure - ≥5% leukemic blasts by bone marrow exam, with no evidence of hematologic response (ie, &lt;30% decrease in % leukemic blasts).
Disease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Adverse Events (CSR 7-April-11)</measure>
    <time_frame>Day 1 up to a maximum of 4 years (includes up to a maximum of 3 cycles of therapy plus 45 days follow up. Related AEs are followed to resolution.)</time_frame>
    <description>Number of participants with treatment emergent adverse events (TEAEs) or death due to related AE. Related AEs for the combination arm can be related to either clofarabine or cytarabine.
Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, Grade 4 = Life Threatening AE, Grade 5 = Death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">326</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>clofarabine (IV formulation) and cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received clofarabine (40 mg/m^2) administered as a 1-hour infusion followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour infusion. Participants could receive up to 3 cycles of treatment (induction, re-induction, and consolidation)
Complete induction cycle = 5 consecutive days of treatment
Re-induction cycle = 5 consecutive days of treatment at the original or modified dose
Consolidation cycle = 4 consecutive days of treatment at the original or modified dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo and cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received placebo administered as a 1-hour infusion followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour infusion. Patients could receive up to 3 cycles of treatment (induction, re-induction, and consolidation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clofarabine (IV formulation)</intervention_name>
    <description>clofarabine (IV formulation) infusion 40mg/m^2 / day up to 3 cycles</description>
    <arm_group_label>clofarabine (IV formulation) and cytarabine</arm_group_label>
    <other_name>Clolar®</other_name>
    <other_name>Evoltra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo (sodium Chloride) 1-hour IV infusion</description>
    <arm_group_label>placebo and cytarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>cytarabine IV infusion 1g/m^2/day for up to 3 cycles</description>
    <arm_group_label>clofarabine (IV formulation) and cytarabine</arm_group_label>
    <arm_group_label>placebo and cytarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of Acute Myelogenous Leukemia (AML) according to World Health
             Organization (WHO) classification

          -  Relapsed after receiving up to 2 prior induction regimens (i.e. first or second
             relapse)or are refractory to not more than one prior combination chemotherapy
             induction regimen

          -  Be ≥ 55 years of age

          -  Have an Eastern Cooperative Oncology Group (ECOG) score of 0-2

          -  Be able to comply with study procedures and follow-up examinations

          -  Be nonfertile or agree to use birth control during the study through the end of
             treatment visit and for at least 90 days after the last dose of study drug

          -  Have adequate liver and renal function as indicated by certain laboratory values

        Exclusion Criteria:

          -  Received previous treatment with clofarabine

          -  Received bolus, intermediate or high-dose cytarabine as induction therapy unless
             certain remission criteria are met

          -  Have received a hematopoietic stem cell transplant (HSCT) within the previous 3 months

          -  Have moderate or severe graft versus host disease (GVHD), whether acute or chronic

          -  Are receiving any other chemotherapy or investigational therapy. Patients must have
             been off prior AML therapy for at least 2-6 weeks prior to entering study.

          -  Have a psychiatric disorder that would interfere with consent, study participation, or
             follow-up

          -  Have an active, uncontrolled infection

          -  Have any other severe concurrent disease, or have a history of serious organ
             dysfunction or disease involving the heart, kidney, liver, or other organ system

          -  Have been diagnosed with another malignancy, unless disease-free for at least 5 years;
             patients with treated nonmelanoma skin cancer, in situ carcinoma, or cervical
             intraepithelial neoplasia, regardless of the disease-free duration, are eligible for
             this study if definitive treatment for the condition has been completed; patients with
             organ-confined prostate cancer with no evidence of recurrent or progressive disease
             are eligible if hormonal therapy has been initiated or the malignancy has been
             surgically removed.

          -  Have clinical evidence suggestive of central nervous system (CNS) involvement with
             leukemia unless lumbar puncture confirms absence of leukemic blasts in the
             cerebrospinal fluid(CSF)

          -  Known HIV positivity

          -  Are pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinical Hospital</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences, Arkansas Cancer Research Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California, Kenneth Norris Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Comprehensive Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Science Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Central Connecticut</name>
      <address>
        <city>Southington</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Northwestern Healthcare</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky, Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Science Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harold Alfond Center for Cancer Care</name>
      <address>
        <city>Augusta</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mecklenburg Medical Group</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center, Simmons Comprehensive Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah - Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Hospitals, Mary Babb Randolph Cancer Center</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John Regional Hospital</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service Maladies du Sang, CHU Angers</name>
      <address>
        <city>Angers Cedex 01</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Zentrum fur Innere Medizin, Abt. Haematologie / Onkologie</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik der Technischen, Universität München</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Bergamo</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O Ospedale Niguarda Ca'Granda</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.O. San Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;Antonio Cardarelli&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Clofarabine + Ara-c improves response rates and event-free survival, not overall survival, in older patients with relapsed/refractory AML compared to Ara-c alone: Updated CLASSIC I study results. H.M. Kantarjian, M. Wetzler, D. Rizzieri, G. J. Schiller, M. H. Jagasia, R. K. Stuart, S. Ganguly, D. Avigan, M. Craig, R. Collins, M. B. Maris, T. Kovacsovics, S. Goldberg, K. Seiter, P. Hari, J. Greiner, N. Vey, C. Recher, F. Ravandi, E.S. Wang, S. Eckert, D. Huebner and S. Faderl. Haematologica - 16th Congress of EHA Abstracts. 2011; 96(S2): 196.</citation>
  </results_reference>
  <results_reference>
    <citation>Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012 Jul 10;30(20):2492-9. doi: 10.1200/JCO.2011.37.9743. Epub 2012 May 14.</citation>
    <PMID>22585697</PMID>
  </results_reference>
  <results_reference>
    <citation>Ganguly S, Kantarjian HM, Wetzler M, Rizzieri D, Schiller G, Jagasia M, et al. Subsequent hematopoietic stem cell transplantation (HSCT) associated with longer survival in patients with relapsed/refractory (R/R) acute myelogenous leukemia (AML) after Clo+Ara-C or Ara-C alone: a landmark analysis from the CLASSIC I trial. Biol Blood Marrow Transplant 2012;18(2Suppl):S211-S212.</citation>
  </results_reference>
  <results_reference>
    <citation>Ganguly S, Kantarjian HM, Wetzler M, Rizzieri D, Schiller G, Jagasia M, et al. Subsequent HSCT in the CLASSIC I Study Associated with Longer Survival in Patients With Relapsed/Refractory AML After Clo+Ara-C Or Ara-C Alone: A Landmark Analysis. Haematologica - 17th Congress of EHA Abstracts. 2012; 97(s1):32</citation>
  </results_reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2006</study_first_submitted>
  <study_first_submitted_qc>April 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2006</study_first_posted>
  <results_first_submitted>August 11, 2011</results_first_submitted>
  <results_first_submitted_qc>August 11, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 15, 2011</results_first_posted>
  <last_update_submitted>March 17, 2014</last_update_submitted>
  <last_update_submitted_qc>March 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute myelogenous leukemia</keyword>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>relapsed AML</keyword>
  <keyword>refractory AML</keyword>
  <keyword>clofarabine</keyword>
  <keyword>cytarabine</keyword>
  <keyword>CLO341</keyword>
  <keyword>clolar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>352 patients screened and 326 randomized, 163 to each treatment group. One participant withdrew after being randomized to the Placebo and Cytarabine Group and was excluded from efficacy analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Clofarabine (IV Formulation) and Cytarabine</title>
          <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
        </group>
        <group group_id="P2">
          <title>Placebo and Cytarabine</title>
          <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="162">AML Centrally Confirmed</participants>
                <participants group_id="P2" count="158">AML Centrally Confirmed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received &gt;= 1 Study Drug (Safety Set)</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41">achieved remission and completed consolidation</participants>
                <participants group_id="P2" count="28">achieved remission and completed consolidation</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="135"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Received Either Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant declined treatment</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Failure</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Recurrence</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Continue to Consolidation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Referred For Transplantation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AML Not Centrally Confirmed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clofarabine (IV Formulation) and Cytarabine</title>
          <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
        </group>
        <group group_id="B2">
          <title>Placebo and Cytarabine</title>
          <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="162"/>
            <count group_id="B2" value="158"/>
            <count group_id="B3" value="320"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.0" spread="6.36"/>
                    <measurement group_id="B2" value="67.1" spread="5.82"/>
                    <measurement group_id="B3" value="67.0" spread="6.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (cm)</title>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.5" spread="10.27"/>
                    <measurement group_id="B2" value="170.5" spread="8.92"/>
                    <measurement group_id="B3" value="171.0" spread="9.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight(kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.21" spread="17.862"/>
                    <measurement group_id="B2" value="83.03" spread="17.281"/>
                    <measurement group_id="B3" value="82.11" spread="17.574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Surface Area (BSA)</title>
          <units>m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.941" spread="0.2383"/>
                    <measurement group_id="B2" value="1.959" spread="0.2338"/>
                    <measurement group_id="B3" value="1.950" spread="0.2359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group Performance Status</title>
          <description>Eastern Cooperative Oncology Group Performance Status (ECOG PS) is a scale ranging from 0-5, with 0 (fully active); 1 (capable of light work); 2 (no work but all self-care); 3 (limited self-care); 4 (completely disabled); 5 (dead).</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ECOG 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karyotype</title>
          <description>Favorable karyotype was defined as any abnormality of chromosome 16; Intermediate karyotype was defined as normal (no abnormalities); Unfavorable karyotype was defined as any other abnormality</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Favorable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unfavorable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival – Overall and by Calculated Strata (CSR 7-April-11)</title>
        <description>Overall survival (OS) for the Full Analysis Set (FAS) and for the 2 calculated strata. OS was defined as the number of months from date of randomization until date of death due to any cause.</description>
        <time_frame>Day 1 (randomization) up to approximately 4 years</time_frame>
        <population>Full Analysis Set (FAS)-all randomized participants whose baseline AML diagnosis was centrally confirmed. Strata are calculated according to duration of the first remission based on case report forms (CRF) data and do not include the IVRS mistakes. One participant's strata (placebo group) could not be calculated so the participant was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Clofarabine (IV Formulation) and Cytarabine (FAS)</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Cytarabine (FAS)</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O3">
            <title>Clofarabine and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O5">
            <title>Clofarabine and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O6">
            <title>Placebo and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival – Overall and by Calculated Strata (CSR 7-April-11)</title>
          <description>Overall survival (OS) for the Full Analysis Set (FAS) and for the 2 calculated strata. OS was defined as the number of months from date of randomization until date of death due to any cause.</description>
          <population>Full Analysis Set (FAS)-all randomized participants whose baseline AML diagnosis was centrally confirmed. Strata are calculated according to duration of the first remission based on case report forms (CRF) data and do not include the IVRS mistakes. One participant's strata (placebo group) could not be calculated so the participant was excluded.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="5.1" upper_limit="9.3"/>
                    <measurement group_id="O2" value="6.4" lower_limit="4.7" upper_limit="7.3"/>
                    <measurement group_id="O3" value="5.1" lower_limit="3.5" upper_limit="8.7"/>
                    <measurement group_id="O4" value="5.5" lower_limit="4.1" upper_limit="7.2"/>
                    <measurement group_id="O5" value="8.7" lower_limit="5.3" upper_limit="11.1"/>
                    <measurement group_id="O6" value="7.2" lower_limit="4.6" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Full Analysis Set (FAS) population</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9951</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Participants stratified by calculated strata remission after first pre-study induction regimen (CR1) &lt; 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4674</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Participants stratified by calculated strata CR1&gt;= 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3963</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Response Per Independent Response Review Panel (IRRP) Assessment – Overall and by Calculated Strata (CSR 7-April-11)</title>
        <description>Percentage of participants whose best response was assessed by the IRRP as complete remission (CR) or complete remission with incomplete peripheral blood count recovery (CRi) using the revised International Working Group for Response Criteria (Cheson 2003).
CR is defined on morphologic criteria at a single response assessment:
a bone marrow aspirate or biopsy of &lt;5% blasts, with evidence of normal hematopoiesis;
absence of Auer rods in the blasts that are present;
absence of extramedullary disease;
absence of a unique phenotype determined at the pretreatment specimen, as assessed by immunophenotyping;
only rare evidence of circulating blasts. If present, evidence of a regenerating bone marrow;
recovery of peripheral counts (platelets ≥100*10^9/L and absolute neutrophil count (ANC) ≥1.0*10^9/L).
CRi met all criteria for CR except for either residual neutropenia (ANC &lt;1.0*10^9/L) or thrombocytopenia (platelet count &lt;100*10^9/L).</description>
        <time_frame>Day 12 up to approximately 6 months</time_frame>
        <population>Full Analysis Set (FAS)-all randomized participants whose baseline AML diagnosis was centrally confirmed. Strata are calculated according to duration of the first remission based on case report forms (CRF) data and do not include the IVRS mistakes. One participant's strata (placebo group) could not be calculated so the participant was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Clofarabine (IV Formulation) and Cytarabine</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Cytarabine</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O3">
            <title>Clofarabine and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O5">
            <title>Clofarabine and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O6">
            <title>Placebo and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
        </group_list>
        <measure>
          <title>Best Response Per Independent Response Review Panel (IRRP) Assessment – Overall and by Calculated Strata (CSR 7-April-11)</title>
          <description>Percentage of participants whose best response was assessed by the IRRP as complete remission (CR) or complete remission with incomplete peripheral blood count recovery (CRi) using the revised International Working Group for Response Criteria (Cheson 2003).
CR is defined on morphologic criteria at a single response assessment:
a bone marrow aspirate or biopsy of &lt;5% blasts, with evidence of normal hematopoiesis;
absence of Auer rods in the blasts that are present;
absence of extramedullary disease;
absence of a unique phenotype determined at the pretreatment specimen, as assessed by immunophenotyping;
only rare evidence of circulating blasts. If present, evidence of a regenerating bone marrow;
recovery of peripheral counts (platelets ≥100*10^9/L and absolute neutrophil count (ANC) ≥1.0*10^9/L).
CRi met all criteria for CR except for either residual neutropenia (ANC &lt;1.0*10^9/L) or thrombocytopenia (platelet count &lt;100*10^9/L).</description>
          <population>Full Analysis Set (FAS)-all randomized participants whose baseline AML diagnosis was centrally confirmed. Strata are calculated according to duration of the first remission based on case report forms (CRF) data and do not include the IVRS mistakes. One participant's strata (placebo group) could not be calculated so the participant was excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Remission (CR + CRi)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9"/>
                    <measurement group_id="O2" value="22.9"/>
                    <measurement group_id="O3" value="45.5"/>
                    <measurement group_id="O4" value="22.9"/>
                    <measurement group_id="O5" value="48.6"/>
                    <measurement group_id="O6" value="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Remission (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2"/>
                    <measurement group_id="O2" value="17.8"/>
                    <measurement group_id="O3" value="33.0"/>
                    <measurement group_id="O4" value="18.1"/>
                    <measurement group_id="O5" value="37.8"/>
                    <measurement group_id="O6" value="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CR with incomplete blood count recovery (CRi)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7"/>
                    <measurement group_id="O2" value="5.1"/>
                    <measurement group_id="O3" value="12.5"/>
                    <measurement group_id="O4" value="4.8"/>
                    <measurement group_id="O5" value="10.8"/>
                    <measurement group_id="O6" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Full Analysis Set (FAS) population - overall remission (OR)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Full Analysis Set (FAS) population - Complete Remission (CR)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Participants stratified by calculated strata - CR1 &lt;6 months [Overall Remission (CR+CRi)]</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Participants stratified by calculated strata - CR1 &gt;=6 months [Overall Remission (CR+CRi)]</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Participants stratified by calculated strata - CR1 &lt;6 months [Complete Remission (CR)]</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0353</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Participants stratified by calculated strata - CR1 &gt;=6 months [Complete Remission (CR)]</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0096</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Remission (DOR) Per IRRP Assessment-Overall and by Calculated Strata (CSR 7-April-11)</title>
        <description>DOR was defined as the time from first CR or CRi to the date of first objective documentation of disease recurrence, initiation of alternative antileukemic therapy [including hematopoietic stem cell transplant] while in remission, or death due to any cause, whichever occurred first.
CR is defined on morphologic criteria at a single response assessment:
a bone marrow aspirate or biopsy of &lt;5% blasts, with evidence of normal hematopoiesis;
absence of Auer rods in the blasts that are present;
absence of extramedullary disease;
absence of a unique phenotype determined at the pretreatment specimen, as assessed by immunophenotyping;
only rare evidence of circulating blasts. If present, evidence of a regenerating bone marrow;
recovery of peripheral counts (platelets ≥100*10^9/L and absolute neutrophil count (ANC) ≥1.0*10^9/L).
CRi met all criteria for CR except for either residual neutropenia (ANC &lt;1.0*10^9/L) or thrombocytopenia (platelet count &lt;100*10^9/L).</description>
        <time_frame>Day 12 to approximately 4 years</time_frame>
        <population>Participants in the FAS who achieved OR (CR + CRi). Strata are calculated according to duration of the first remission based on case report forms (CRF) data and do not include the IVRS mistakes.</population>
        <group_list>
          <group group_id="O1">
            <title>Clofarabine (IV Formulation) and Cytarabine</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Cytarabine</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O3">
            <title>Clofarabine and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O5">
            <title>Clofarabine and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O6">
            <title>Placebo and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Remission (DOR) Per IRRP Assessment-Overall and by Calculated Strata (CSR 7-April-11)</title>
          <description>DOR was defined as the time from first CR or CRi to the date of first objective documentation of disease recurrence, initiation of alternative antileukemic therapy [including hematopoietic stem cell transplant] while in remission, or death due to any cause, whichever occurred first.
CR is defined on morphologic criteria at a single response assessment:
a bone marrow aspirate or biopsy of &lt;5% blasts, with evidence of normal hematopoiesis;
absence of Auer rods in the blasts that are present;
absence of extramedullary disease;
absence of a unique phenotype determined at the pretreatment specimen, as assessed by immunophenotyping;
only rare evidence of circulating blasts. If present, evidence of a regenerating bone marrow;
recovery of peripheral counts (platelets ≥100*10^9/L and absolute neutrophil count (ANC) ≥1.0*10^9/L).
CRi met all criteria for CR except for either residual neutropenia (ANC &lt;1.0*10^9/L) or thrombocytopenia (platelet count &lt;100*10^9/L).</description>
          <population>Participants in the FAS who achieved OR (CR + CRi). Strata are calculated according to duration of the first remission based on case report forms (CRF) data and do not include the IVRS mistakes.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="5.4" upper_limit="11.5"/>
                    <measurement group_id="O2" value="3.8" lower_limit="3.3" upper_limit="12.1"/>
                    <measurement group_id="O3" value="5.7" lower_limit="5.3" upper_limit="7.7"/>
                    <measurement group_id="O4" value="6.3" lower_limit="2.3" upper_limit="7.2"/>
                    <measurement group_id="O5" value="11.5" lower_limit="6.8" upper_limit="15.5"/>
                    <measurement group_id="O6" value="3.8" lower_limit="3.3">N/A = There were an insufficient number of events to allow estimation of the upper limit.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Remission (DOR) Per IRRP Assessment-Overall and by Randomized Strata (CSR 9-July-12)</title>
        <description>DOR was defined as the time from first CR or CRi to the date of first objective documentation of disease recurrence, initiation of alternative antileukemic therapy [including hematopoietic stem cell transplant] while in remission, or death due to any cause, whichever occurred first.
CR is defined on morphologic criteria at a single response assessment:
a bone marrow aspirate or biopsy of &lt;5% blasts, with evidence of normal hematopoiesis;
absence of Auer rods in the blasts that are present;
absence of extramedullary disease;
absence of a unique phenotype determined at the pretreatment specimen, as assessed by immunophenotyping;
only rare evidence of circulating blasts. If present, evidence of a regenerating bone marrow;
recovery of peripheral counts (platelets ≥100*10^9/L and absolute neutrophil count (ANC) ≥1.0*10^9/L).
CRi met all criteria for CR except for either residual neutropenia (ANC &lt;1.0*10^9/L) or thrombocytopenia (platelet count &lt;100*10^9/L).</description>
        <time_frame>Day 12 to approximately 4 years</time_frame>
        <population>Participants in the FAS who achieved OR (CR + CRi). Strata are as randomized by the IVRS, therefore strata include the IVRS mistakes.</population>
        <group_list>
          <group group_id="O1">
            <title>Clofarabine (IV Formulation) and Cytarabine</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Cytarabine</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O3">
            <title>Clofarabine and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O5">
            <title>Clofarabine and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O6">
            <title>Placebo and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Remission (DOR) Per IRRP Assessment-Overall and by Randomized Strata (CSR 9-July-12)</title>
          <description>DOR was defined as the time from first CR or CRi to the date of first objective documentation of disease recurrence, initiation of alternative antileukemic therapy [including hematopoietic stem cell transplant] while in remission, or death due to any cause, whichever occurred first.
CR is defined on morphologic criteria at a single response assessment:
a bone marrow aspirate or biopsy of &lt;5% blasts, with evidence of normal hematopoiesis;
absence of Auer rods in the blasts that are present;
absence of extramedullary disease;
absence of a unique phenotype determined at the pretreatment specimen, as assessed by immunophenotyping;
only rare evidence of circulating blasts. If present, evidence of a regenerating bone marrow;
recovery of peripheral counts (platelets ≥100*10^9/L and absolute neutrophil count (ANC) ≥1.0*10^9/L).
CRi met all criteria for CR except for either residual neutropenia (ANC &lt;1.0*10^9/L) or thrombocytopenia (platelet count &lt;100*10^9/L).</description>
          <population>Participants in the FAS who achieved OR (CR + CRi). Strata are as randomized by the IVRS, therefore strata include the IVRS mistakes.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="5.7" upper_limit="11.5"/>
                    <measurement group_id="O2" value="3.8" lower_limit="3.3" upper_limit="12.1"/>
                    <measurement group_id="O3" value="6.7" lower_limit="4.0" upper_limit="8.8"/>
                    <measurement group_id="O4" value="6.3" lower_limit="2.3" upper_limit="7.2"/>
                    <measurement group_id="O5" value="10.2" lower_limit="6.8" upper_limit="20.2"/>
                    <measurement group_id="O6" value="3.8" lower_limit="3.3">There were an insufficient number of events to allow estimation of the upper limit.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival by IRRP Assessment - Overall and by Calculated Strata (CSR 7-April-11)</title>
        <description>Disease-free survival was defined as the time from first complete remission (CR) or complete remission with incomplete peripheral blood count recovery (CRi) until the date of first objective documentation of disease recurrence or death due to any cause, whichever occurred first.
See Outcome #3 for definition of CR and CRi.
Disease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.</description>
        <time_frame>Day 12 to approximately 4 years</time_frame>
        <population>Participants in the FAS who achieved OR (CR + CRi). Strata are calculated according to duration of the first remission based on case report forms (CRF) data and do not include the IVRS mistakes.</population>
        <group_list>
          <group group_id="O1">
            <title>Clofarabine (IV Formulation) and Cytarabine</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Cytarabine</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O3">
            <title>Clofarabine and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O5">
            <title>Clofarabine and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O6">
            <title>Placebo and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival by IRRP Assessment - Overall and by Calculated Strata (CSR 7-April-11)</title>
          <description>Disease-free survival was defined as the time from first complete remission (CR) or complete remission with incomplete peripheral blood count recovery (CRi) until the date of first objective documentation of disease recurrence or death due to any cause, whichever occurred first.
See Outcome #3 for definition of CR and CRi.
Disease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.</description>
          <population>Participants in the FAS who achieved OR (CR + CRi). Strata are calculated according to duration of the first remission based on case report forms (CRF) data and do not include the IVRS mistakes.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="6.7" upper_limit="10.3"/>
                    <measurement group_id="O2" value="7.0" lower_limit="3.9" upper_limit="12.1"/>
                    <measurement group_id="O3" value="5.7" lower_limit="4.4" upper_limit="9.7"/>
                    <measurement group_id="O4" value="6.7" lower_limit="3.9" upper_limit="8.1"/>
                    <measurement group_id="O5" value="10.3" lower_limit="7.5" upper_limit="15.5"/>
                    <measurement group_id="O6" value="9.1" lower_limit="3.7">NA = There were an insufficient number of events to allow estimation of the upper limit.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival by IRRP Assessment - Overall and by Randomized Strata (CSR 9-July-12)</title>
        <description>Disease-free survival was defined as the time from first complete remission (CR) or complete remission with incomplete peripheral blood count recovery (CRi) until the date of first objective documentation of disease recurrence or death due to any cause, whichever occurred first.
See Outcome #3 for definition of CR and CRi.
Disease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.</description>
        <time_frame>Day 12 to approximately 4 years</time_frame>
        <population>Participants in the FAS who achieved OR (CR + CRi). Strata are as randomized by the IVRS, therefore strata include the IVRS mistakes.</population>
        <group_list>
          <group group_id="O1">
            <title>Clofarabine (IV Formulation) and Cytarabine</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Cytarabine</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O3">
            <title>Clofarabine and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O5">
            <title>Clofarabine and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O6">
            <title>Placebo and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival by IRRP Assessment - Overall and by Randomized Strata (CSR 9-July-12)</title>
          <description>Disease-free survival was defined as the time from first complete remission (CR) or complete remission with incomplete peripheral blood count recovery (CRi) until the date of first objective documentation of disease recurrence or death due to any cause, whichever occurred first.
See Outcome #3 for definition of CR and CRi.
Disease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.</description>
          <population>Participants in the FAS who achieved OR (CR + CRi). Strata are as randomized by the IVRS, therefore strata include the IVRS mistakes.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="6.9" upper_limit="15.4"/>
                    <measurement group_id="O2" value="7.0" lower_limit="3.9" upper_limit="9.8"/>
                    <measurement group_id="O3" value="6.7" lower_limit="3.9" upper_limit="9.7"/>
                    <measurement group_id="O4" value="6.7" lower_limit="3.9" upper_limit="8.1"/>
                    <measurement group_id="O5" value="15.4" lower_limit="9.2" upper_limit="20.5"/>
                    <measurement group_id="O6" value="9.2" lower_limit="3.7" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival by IRRP Assessment – Overall and by Calculated Strata (CSR 7-April-11)</title>
        <description>Event-free survival (EFS) was defined as the time from randomization to the date of treatment failure, first disease recurrence (for participants who achieved remission), or death due to any cause, whichever occurred first.
Treatment Failure - ≥5% leukemic blasts by bone marrow exam, with no evidence of hematologic response (ie, &lt;30% decrease in % leukemic blasts).
Disease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.</description>
        <time_frame>Day 1 (randomization) up to approximately 4 years</time_frame>
        <population>Full Analysis Set (FAS)-all randomized participants whose baseline AML diagnosis was centrally confirmed. Strata are calculated according to duration of the first remission based on case report forms (CRF) data and do not include the IVRS mistakes. One participant's strata (placebo group) could not be calculated so the participant was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Clofarabine (IV Formulation) and Cytarabine</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Cytarabine</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O3">
            <title>Clofarabine and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O5">
            <title>Clofarabine and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O6">
            <title>Placebo and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival by IRRP Assessment – Overall and by Calculated Strata (CSR 7-April-11)</title>
          <description>Event-free survival (EFS) was defined as the time from randomization to the date of treatment failure, first disease recurrence (for participants who achieved remission), or death due to any cause, whichever occurred first.
Treatment Failure - ≥5% leukemic blasts by bone marrow exam, with no evidence of hematologic response (ie, &lt;30% decrease in % leukemic blasts).
Disease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.</description>
          <population>Full Analysis Set (FAS)-all randomized participants whose baseline AML diagnosis was centrally confirmed. Strata are calculated according to duration of the first remission based on case report forms (CRF) data and do not include the IVRS mistakes. One participant's strata (placebo group) could not be calculated so the participant was excluded.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.1" upper_limit="2.9"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.9" upper_limit="1.1"/>
                    <measurement group_id="O3" value="1.4" lower_limit="1.0" upper_limit="2.9"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.7" upper_limit="1.2"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.2" upper_limit="6.6"/>
                    <measurement group_id="O6" value="1.0" lower_limit="0.9" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Full Analysis Set (FAS) population.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Participants stratified by randomization strata CR1 &lt;6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0131</p_value>
            <method>Log Rank</method>
            <method_desc>Comparison P-value is from a log-rank test with no strata</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Participants stratified by randomization strata CR1 &gt;=6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <method>Log Rank</method>
            <method_desc>Comparison p-value is from a log-rank test with no strata.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival - Overall and by Randomized Strata (CSR 9-July-12)</title>
        <description>Overall survival (OS) for the Full Analysis Set (FAS) and for the 2 randomized strata. OS was defined as the number of months from date of randomization until date of death due to any cause.</description>
        <time_frame>Day 1 (randomization) up to approximately 4 years</time_frame>
        <population>Full Analysis Set (FAS) - composed of all randomized participants whose baseline AML diagnosis was centrally confirmed. Strata are as randomized by the IVRS, therefore strata include the IVRS mistakes.</population>
        <group_list>
          <group group_id="O1">
            <title>Clofarabine (IV Formulation) and Cytarabine (FAS)</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Cytarabine (FAS)</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O3">
            <title>Clofarabine and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O5">
            <title>Clofarabine and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O6">
            <title>Placebo and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival - Overall and by Randomized Strata (CSR 9-July-12)</title>
          <description>Overall survival (OS) for the Full Analysis Set (FAS) and for the 2 randomized strata. OS was defined as the number of months from date of randomization until date of death due to any cause.</description>
          <population>Full Analysis Set (FAS) - composed of all randomized participants whose baseline AML diagnosis was centrally confirmed. Strata are as randomized by the IVRS, therefore strata include the IVRS mistakes.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="76"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="5.1" upper_limit="9.3"/>
                    <measurement group_id="O2" value="6.3" lower_limit="4.7" upper_limit="7.3"/>
                    <measurement group_id="O3" value="4.8" lower_limit="2.9" upper_limit="7.3"/>
                    <measurement group_id="O4" value="6.3" lower_limit="4.1" upper_limit="7.8"/>
                    <measurement group_id="O5" value="9.7" lower_limit="5.9" upper_limit="12.7"/>
                    <measurement group_id="O6" value="6.6" lower_limit="4.3" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Full Analysis Set (FAS) population</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8209</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5071</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2906</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival by IRRP Assessment – Overall and by Randomized Strata (CSR 9-July-12)</title>
        <description>Event-free survival (EFS) was defined as the time from randomization to the date of treatment failure, first disease recurrence (for participants who achieved remission), or death due to any cause, whichever occurred first.
Treatment Failure - ≥5% leukemic blasts by bone marrow exam, with no evidence of hematologic response (ie, &lt;30% decrease in % leukemic blasts).
Disease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.</description>
        <time_frame>Day 1 (randomization) up to approximately 4 years</time_frame>
        <population>Full Analysis Set - composed of all randomized participants whose baseline AML diagnosis was centrally confirmed. Strata are as randomized by the IVRS, therefore strata include the IVRS mistakes.</population>
        <group_list>
          <group group_id="O1">
            <title>Clofarabine (IV Formulation) and Cytarabine</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Cytarabine</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O3">
            <title>Clofarabine and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O5">
            <title>Clofarabine and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O6">
            <title>Placebo and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival by IRRP Assessment – Overall and by Randomized Strata (CSR 9-July-12)</title>
          <description>Event-free survival (EFS) was defined as the time from randomization to the date of treatment failure, first disease recurrence (for participants who achieved remission), or death due to any cause, whichever occurred first.
Treatment Failure - ≥5% leukemic blasts by bone marrow exam, with no evidence of hematologic response (ie, &lt;30% decrease in % leukemic blasts).
Disease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.</description>
          <population>Full Analysis Set - composed of all randomized participants whose baseline AML diagnosis was centrally confirmed. Strata are as randomized by the IVRS, therefore strata include the IVRS mistakes.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="76"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.1" upper_limit="2.9"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.8" upper_limit="1.1"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.8" upper_limit="2.5"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.7" upper_limit="1.2"/>
                    <measurement group_id="O5" value="2.8" lower_limit="1.2" upper_limit="8.1"/>
                    <measurement group_id="O6" value="1.0" lower_limit="0.8" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Full Analysis Set (FAS) population.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0486</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Four-Month Event-free Survival Per IRRP Assessment – Overall and by Calculated Strata (CSR 7-April-11)</title>
        <description>Four-month event-free survival (EFS) was defined as achieving an EFS of at least 122 days, where EFS is defined as the time from randomization to the date of treatment failure, first disease recurrence (for participants who achieved remission), or death due to any cause, whichever occurred first.
Treatment Failure - ≥5% leukemic blasts by bone marrow exam, with no evidence of hematologic response (ie, &lt;30% decrease in % leukemic blasts).
Disease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.</description>
        <time_frame>Day 1 (randomization) to Day 122</time_frame>
        <population>Full Analysis Set (FAS)-all randomized participants whose baseline AML diagnosis was centrally confirmed. Strata are calculated according to duration of the first remission based on case report forms (CRF) data and do not include the IVRS mistakes. One participant's strata (placebo group) could not be calculated so the participant was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Clofarabine (IV Formulation) and Cytarabine</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Cytarabine</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O3">
            <title>Clofarabine and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O5">
            <title>Clofarabine and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O6">
            <title>Placebo and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
        </group_list>
        <measure>
          <title>Four-Month Event-free Survival Per IRRP Assessment – Overall and by Calculated Strata (CSR 7-April-11)</title>
          <description>Four-month event-free survival (EFS) was defined as achieving an EFS of at least 122 days, where EFS is defined as the time from randomization to the date of treatment failure, first disease recurrence (for participants who achieved remission), or death due to any cause, whichever occurred first.
Treatment Failure - ≥5% leukemic blasts by bone marrow exam, with no evidence of hematologic response (ie, &lt;30% decrease in % leukemic blasts).
Disease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.</description>
          <population>Full Analysis Set (FAS)-all randomized participants whose baseline AML diagnosis was centrally confirmed. Strata are calculated according to duration of the first remission based on case report forms (CRF) data and do not include the IVRS mistakes. One participant's strata (placebo group) could not be calculated so the participant was excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7"/>
                    <measurement group_id="O2" value="16.6"/>
                    <measurement group_id="O3" value="35.2"/>
                    <measurement group_id="O4" value="16.9"/>
                    <measurement group_id="O5" value="40.5"/>
                    <measurement group_id="O6" value="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Full Analysis Set (FAS) population</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Participants stratified by randomization strata CR1 &lt;6 months.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0088</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Participants stratified by randomization strata CR1 &gt;=6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0017</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Four-Month Event-free Survival Per IRRP Assessment – Overall and by Randomized Strata (CSR 9-July-12)</title>
        <description>Four-month event-free survival (EFS) was defined as achieving an EFS of at least 122 days, where EFS is defined as the time from randomization to the date of treatment failure, first disease recurrence (for participants who achieved remission), or death due to any cause, whichever occurred first.
Treatment Failure - ≥5% leukemic blasts by bone marrow exam, with no evidence of hematologic response (ie, &lt;30% decrease in % leukemic blasts).
Disease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.</description>
        <time_frame>Day 1 (randomization) to Day 122</time_frame>
        <population>Full Analysis Set - composed of all randomized participants whose baseline AML diagnosis was centrally confirmed. Strata are as randomized by the IVRS, that is the strata include the IVRS mistakes.</population>
        <group_list>
          <group group_id="O1">
            <title>Clofarabine (IV Formulation) and Cytarabine</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Cytarabine</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O3">
            <title>Clofarabine and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Cytarabine - In Stratum &lt; 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
          <group group_id="O5">
            <title>Clofarabine and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O6">
            <title>Placebo and Cytarabine In Stratum &gt;= 6 Months</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
        </group_list>
        <measure>
          <title>Four-Month Event-free Survival Per IRRP Assessment – Overall and by Randomized Strata (CSR 9-July-12)</title>
          <description>Four-month event-free survival (EFS) was defined as achieving an EFS of at least 122 days, where EFS is defined as the time from randomization to the date of treatment failure, first disease recurrence (for participants who achieved remission), or death due to any cause, whichever occurred first.
Treatment Failure - ≥5% leukemic blasts by bone marrow exam, with no evidence of hematologic response (ie, &lt;30% decrease in % leukemic blasts).
Disease recurrence - reappearance of leukemic blasts in the peripheral blood, confirmed by ≥5% blasts in the bone marrow, and reappearance or development of pathologically proven extramedullary disease.</description>
          <population>Full Analysis Set - composed of all randomized participants whose baseline AML diagnosis was centrally confirmed. Strata are as randomized by the IVRS, that is the strata include the IVRS mistakes.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="76"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9"/>
                    <measurement group_id="O2" value="17.1"/>
                    <measurement group_id="O3" value="31.4"/>
                    <measurement group_id="O4" value="17.9"/>
                    <measurement group_id="O5" value="47.4"/>
                    <measurement group_id="O6" value="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0506</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Adverse Events (CSR 7-April-11)</title>
        <description>Number of participants with treatment emergent adverse events (TEAEs) or death due to related AE. Related AEs for the combination arm can be related to either clofarabine or cytarabine.
Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, Grade 4 = Life Threatening AE, Grade 5 = Death</description>
        <time_frame>Day 1 up to a maximum of 4 years (includes up to a maximum of 3 cycles of therapy plus 45 days follow up. Related AEs are followed to resolution.)</time_frame>
        <population>Safety Set - Participants in the Full Analysis Set (FAS) who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Clofarabine (IV Formulation) and Cytarabine</title>
            <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Cytarabine</title>
            <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Adverse Events (CSR 7-April-11)</title>
          <description>Number of participants with treatment emergent adverse events (TEAEs) or death due to related AE. Related AEs for the combination arm can be related to either clofarabine or cytarabine.
Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, Grade 4 = Life Threatening AE, Grade 5 = Death</description>
          <population>Safety Set - Participants in the Full Analysis Set (FAS) who received at least 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Treatment Emergent AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Related Treatment Emergent AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Treatment Emergent Grade &gt;=3 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Related Treatment Related Grade &gt;=3 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinue of study medication due to AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinue of study medication due to related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 up to a maximum of 4 years (includes up to a maximum of 3 cycles of therapy plus 45 days follow up. Related AEs are followed to resolution.)</time_frame>
      <desc>In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (&quot;number of affected participants&quot;) of both adverse event tables. Adverse event information is from the final database supporting the clinical study report dated 9-July-12.</desc>
      <group_list>
        <group group_id="E1">
          <title>Clofarabine (IV Formulation) and Cytarabine</title>
          <description>Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction (if the participant had not achieved remission following induction but hematological improvement was noted), and consolidation.</description>
        </group>
        <group group_id="E2">
          <title>Placebo and Cytarabine</title>
          <description>Participants received placebo (sodium chloride) administered as a 1-hour IV infusion, followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction, re-induction, and consolidation.</description>
        </group>
        <group group_id="E3">
          <title>Overall</title>
          <description>Combined total for the two Arms/Groups</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="173" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Caecitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Venoocclusive liver disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Alpha haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Corynebacterium sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Enterobacter bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Enterobacter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Keratitis herpetic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Serratia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Staphylococcal scalded skin syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Upper respiratory fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Zygomycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Refractoriness to platelet transfusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Muscle disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Peripheral sensorimotor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Exfoliative rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Generalised erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Toxic epidermal necrolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="161" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="315" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Febrile bone marrow aplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Haemoglobinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypercoagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hyperfibrinogenaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypofibrinogenaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypoprothrombinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lymphatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Monocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Aortic valve calcification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cardiac aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dilatation atrial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dilatation ventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Heart valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Left atrial dilatation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pulmonary valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ventricular hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ear congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hyperadrenalism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Conjunctival cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Conjunctival pallor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Erythema of eyelid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gaze palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Miosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ocular dysmetria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ocular icterus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Optic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pupillary reflex impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pupils unequal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Scleral disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Scleral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Scleral oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Anal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Caecitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Chapped lips</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Colonic pseudo-obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="138" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="172" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gastric antral vascular ectasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gastrointestinal sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gingival cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Intestinal dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lip blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lip haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lip ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Mucous stools</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="199" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Neutropenic colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oesophageal dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oesophageal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oral mucosal discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oral mucosal erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Parotid gland enlargement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Poor dental condition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rectal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tongue blistering</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tongue coated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tongue discolouration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tongue exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tongue haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tongue ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Catheter site discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Catheter site erosion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Catheter site erythema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Catheter site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Catheter site oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Catheter site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Catheter site rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Catheter site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Crepitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Early satiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="106" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Infusion site discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Infusion site induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Mucosal dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="153" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Visceral oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dilatation intrahepatic duct acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hepatic lesion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hepatosplenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypogammaglobulinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Alpha haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bullous impetigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Candida pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Catheter site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cystitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Enterobacter bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Eye infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Eye infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hepatosplenic candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Micrococcus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pulmonary mycosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Septic embolus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Serratia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Sinusitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Staphylococcal scalded skin syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Stenotrophomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Urinary tract infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Viral skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Eschar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lip injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Nail avulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Nail injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Post procedural swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Refractoriness to platelet transfusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tongue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Urethral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ammonia increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bacterial test</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blast cells present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood beta-D-glucan increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood chloride decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood chloride increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood culture positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood iron increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood magnesium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood osmolarity increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood phosphorus increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Catheter culture positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Clostridium test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Crystal urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Culture stool positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Culture throat positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Culture urine positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Diagnostic procedure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Electrocardiogram PR shortened</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST-T segment abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Enterococcus test positive</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Escherichia test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Fungal test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gallop rhythm present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Liver scan abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lymph node palpable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Monocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Nitrite urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Protein total decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Protein total increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pulmonary function test decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>QRS axis abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Red blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Right ventricular systolic pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Serum ferritin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Spleen palpable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Staphylococcus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Streptococcus test positive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Total lung capacity decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Urinary sediment present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Urine leukocyte esterase positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>pH urine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Folate deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hyperamylasaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hyperlipasaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypermagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Iron overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Vitamin K deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bone loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Chondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Coccydynia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Muscle atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Osteolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Osteosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign neoplasm of eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Eye naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lip neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Neurilemmoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Apraxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cranial nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Encephalitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="112" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypogeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hyporeflexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Intention tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Slow speech</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Anger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Fear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Flat affect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bladder mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Enuresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Kidney enlargement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Urethritis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Urine abnormality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Urine flow decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Breast haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Penile blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Penile haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Penile pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Scrotal oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Vulvovaginal rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Vulvovaginal swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bronchial wall thickening</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Increased bronchial secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Laryngospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Nasal mucosal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Nasal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oropharyngeal blistering</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Oropharyngeal plaque</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Paranasal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pharyngeal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Respiratory alkalosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rhinalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Sputum discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Throat lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Blood blister</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Exfoliative rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Generalised erythema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Increased tendency to bruise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lentigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Leukocytoclastic vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Nail dystrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Palmar erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Photodermatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pigmentation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rash follicular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rash vesicular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Skin haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Subcutaneous nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Andropause</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Aortic arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Aortic calcification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Aortic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Jugular vein distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Vascular stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Genzyme Medical Information</name_or_title>
      <organization>Genzyme Corporation</organization>
      <phone>800-745-4447</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

